(Q42632976)

4 November 2017

title

Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections (English)

1 reference

4 November 2017

main subject

urinary tract infection

1 reference

hospital-acquired infection

inferred from title

1 reference

R Sharifi

1 reference

4 November 2017

R Geckler

series ordinal

1 reference

4 November 2017

S Childs

series ordinal

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 June 1996

1 reference

American Journal of Medicine

4 November 2017

published in

1 reference

4 November 2017

volume

100

1 reference

4 November 2017

1 reference

4 November 2017

page(s)

76S-82S

1 reference

An overview of nosocomial infections, including the role of the microbiology laboratory

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Use of plasmid analysis to determine the source of bacterial invasion of the urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Nosocomial klebsiella infections: intestinal colonization as a reservoir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Major trends in the microbial etiology of nosocomial infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Emergence of vancomycin resistance in coagulase-negative staphylococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Molecular characterization of the gene encoding SHV-3 beta-lactamase responsible for transferable cefotaxime resistance in clinical isolates of Klebsiella pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Broad-spectrum beta-lactam resistance in Enterobacter: emergence during treatment and mechanisms of resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

USA resistance patterns among UTI pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

In-vitro antibacterial activity of cefepime: a multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

In-vitro activity of cefepime and other antimicrobials: survey of European isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Activity of cefepime and other beta-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Low-dosage cefepime as treatment for serious bacterial infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900112-X

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/S0002-9343(96)00112-X

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xbv23u55bfefjauhywnaezm5um

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_xbv23u55bfefjauhywnaezm5um

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xbv23u55bfefjauhywnaezm5um

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/xbv23u55bfefjauhywnaezm5um

1 reference

30 July 2022